Pharmacokinetics and Pharmacodynamics – Medicines and the Body
Published: 31 December 2017
Published: 31 December 2017
Medicines aim to prevent, cure or control various disease states. To achieve this goal, adequate concentrations of the medicine must be delivered to the target tissues so that therapeutic, yet nontoxic levels, are obtained.
Pharmacological and toxicological actions of medicines are primarily related to their plasma concentrations. Consequently, healthcare professionals involved with medicines must recognise the onset speed of medicine action as well as the intensity and duration of its effect. In turn, these are controlled by the following four fundamental pathways of drug movement and modification in the body:
Pharmacokinetics influences the decided route of administration for a specific medication, the amount and frequency of each dose and its dosing intervals.
On the other hand, pharmacodynamics is the study of how a medicine acts on a living organism. This includes the pharmacological response and its duration and magnitude observed, relative to the medicines concentration at an active site in the organism; i.e. the study of a medicine’s effect and the mechanisms of action.
Clinical pharmacokinetics is the application of pharmacokinetic and pharmacodynamic principles to the safe and effective therapeutic management of an individual patient.
The pharmacokinetic term half-life (t1/2) refers to the time taken for half the initial dose of medicine administered to be eliminated from the body, i.e.:
Many medications are classified in terms of their half-lives. For example the benzodiazepines are classified in terms of:
Below is a schematic representation of the absorption, distribution, metabolism and excretion of medicines.
Alternatively, the following graph represents a medicine’s absorption, distribution, metabolism and excretion, along with some pharmacokinetic terms, after a single oral immediate-release dose.
Absorption from the site of administration permits entry of the therapeutic agent (either directly or indirectly) into plasma.
Medicine-related factors include ionisation state, molecular weight, solubility, and formulation. Small, nonionised, lipid-soluble medicines permeate plasma membranes most readily.
Once absorbed, the medicine may then reversibly leave the bloodstream and distribute into the interstitial and intracellular fluids.
A medicine’s permeability is defined by the blood-brain barrier, blood-testes barrier and blood-placenta barrier.
Most medicines are protein bound to some extent; only an unbound medicine is free to carry out its pharmacological action(s).
Depot Storage refers to lipophilic medicines which store in fat, calcium-binding drugs, etc.
The volume of distribution is the extent to which a medicine distributes out of the bloodstream and into the tissues of the body (i.e. the site of drug receptors). A decrease in Vd will result in higher plasma concentrations for hydrophilic medicines such as gentamicin, digoxin and lithium. A higher proportion of body fat will increase Vd for lipophilic medicines such as diazepam causing an increase in plasma half-life.
Before being excreted, the medicine is metabolised by the liver, kidney or other sites. It refers to the process of making the drug more polar (more water-soluble), which may lead to medicine inactivation and excretion.
Metabolites may be more or less (prodrug) active than the parent medicine. The liver is the major source of these enzymes (P450 enzymes), though they may be present in the gastrointestinal tract, heart, lung, brain and kidney.
Phase I reactions (nonsynthetic) involve minor structural modifications of the parent structure via oxidation, reduction or hydrolysis to produce smaller, more water-soluble metabolite. These are predominantly handled by enzymes known as the Cytochrom P450 enzymes.
Phase I reactions frequently provide a ‘handle’ for further modifications by subsequent Phase II reactions.
Phase II reactions (synthetic) involve the coupling of a water-soluble endogenous molecule such as glucuronic acid, sulfate, glutathione to a chemical (parent compound and/or Phase I metabolite) to facilitate excretion.
The most common causes of medicine-to-medicine interactions are pharmacokinetics, particularly metabolic ones. These are known as the cytochrome P450 interactions.
A large number of clinically important interactions arise from inhibition or induction of substrates (medicines that are significantly metabolised by the given enzymes).
Medicines and their metabolites are removed from the body in urine, bile and/or faeces. Some cases first need to be metabolised to more water-soluble moieties (examples include amiodarone, amitriptyline, amlodipine, amphotericin B, aripiprazole, aspirin, atomoxetine, atorvastatin, azithromycin, felodipine etc.)
Others are excreted unchanged or relatively unchanged (penicillins, cephalosporins, aminoglycosides, ganciclovir, milrinone, oseltamivir, risedronate, varenicline etc.).
The main processes involved in excretion are glomerular filtration, tubular secretion and tubular reabsorption.
Tubular excretion and reabsorption may also be influenced by medications that either make the urine more acid (ammonium chloride, large doses of vitamin C), or more alkaline ((urinary alkalisers such as Citralite®, Citravescent®, Uracol®, Ural® – all raise the urinary pH to about pH 9).
Creatinine (Normal range: Females 50-110 micromol /L; Males 60-120 micromol /L) is the metabolic product of muscle metabolism. Its level is a reflection of both muscle mass and kidney function, as creatinine is predominantly eliminated by glomerular filtration through the kidney.
Low levels may indicate protein starvation, liver disease or pregnancy, whereas high levels are seen in kidney failure, muscle degeneration, and effects of some medicines which block renal secretion (e.g. cimetidine and trimethoprim).
Creatinine clearance (CrCl) is an estimate of the glomerular filtration rate (GFR) which is a direct measure of renal function. The CrCl can be calculated by means of the Cockroft-Gault Equation:
(For females multiply by 0.85 to account for the reduced muscle to ideal body weight ratio in comparison to males.)
(Many monographs on medicines will indicate dose and dose frequency of a medicine according to the Creatinine Clearance.)
eGFR is used by the pathology labs as an estimated indicator of renal function. (eGFR has limitations and for medicine dosing when renal function is <60mL/min the Cockcroft -Gault equation is preferable.)
Bioavailability is a subcategory of absorption and is the fraction of an administered dose of unchanged medicine that reaches the systemic circulation. By definition when a medication is administered intravenously, its (absolute) bioavailability is 100 per cent.
Efficacy of a drug is a function of the rate and extent of absorption. Relative bioavailability is derived as a relationship (%) between the bioavailability from an oral dose-form (or other non-IV dose) relative to an IV dose.
Which one of the following statements is not correct?
[show_more more=”Reveal Answer?” less=”Hide Answer” align=”center” color=”#000000″]
Answer: D – Creatinine clearance (CrCl) is NOT a direct measure of renal function; it is a derived measure.
Associate Professor Louis Roller has been an academic at the Faculty of Pharmacy and Pharmaceutical Sciences Monash University for over 50 years. He was on the Pharmacy Board of Victoria for 22 years and has significantly contributed to many editions of various pharmaceutical compendia, including the Therapeutic Guidelines, particularly the Antibiotic Guidelines. He is the author of hundreds of scientific and professional articles and has a passion for evidence-based knowledge. He lectures to pharmacists, medical practitioners, nurses, podiatrists, and optometrists on a variety of therapeutic topics, particularly antibiotics, as well as giving many talks to the University of the Third Age on various medication-related issues. As at the end of April, he had delivered 42 talks to U3A Stonnington and an equivalent number to other U3A groups. With Dr Jenny Gowan, over the last 20 years, he has written articles on disease state management in the Australian Journal of Pharmacy. In 2012, he was made a life member of the Australasian Pharmaceutical Sciences Association and, in 2014, he was awarded the life-long achievement award of the Pharmaceutical Society of Australia.